鞘内注射巴氯芬治疗失败和纳布啡醇在多发性硬化相关痉挛中的超相加作用：病例报告。
Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: a case report.
机构信息
Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Gudrunstr. 56, D-44791 Bochum, Germany.
出版信息
Ther Adv Neurol Disord. 2013 May;6(3):199-203. doi: 10.1177/1756285613475835.
Abstract
Multiple sclerosis (MS)-related spasticity is associated with disability and impairment in quality of life. We report on a patient with secondary progressive MS and spastic tetraparesis (Expanded Disability Status Scale score 8.5). The right arm exhibited flexor spasticity resulting in functional disability despite multimodal symptomatic treatment. Intrathecal baclofen led to side effects despite decreasing efficacy. Low-dose nabiximols improved spasticity and function with recovery of daily-life activities and spasticity-related symptoms. Reduction of intrathecal baclofen ameliorated adverse drug reactions. Add-on cannabinoid therapy was effective in therapy-refractory spasticity with supra-additive effect in combining intrathecal baclofen and nabiximols, hypothetically explained by mutually complementing mechanisms of action.
摘要
多发性硬化症（MS）相关的痉挛与残疾和生活质量受损有关。我们报告了一例继发进展型 MS 伴痉挛性四肢瘫痪患者（扩展残疾状况量表评分 8.5）。右臂出现屈肌痉挛，尽管进行了多模式对症治疗，但仍导致功能障碍。尽管降低了疗效，但鞘内巴氯芬仍导致不良反应。低剂量纳比昔醇改善了痉挛和功能，恢复了日常生活活动和与痉挛相关的症状。减少鞘内巴氯芬可改善药物不良反应。在鞘内巴氯芬和纳比昔醇联合治疗中，附加的大麻素治疗对难治性痉挛有效，具有超相加效应，这可以用相互补充的作用机制来解释。
相似文献
1
Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: a case report.鞘内注射巴氯芬治疗失败和纳布啡醇在多发性硬化相关痉挛中的超相加作用：病例报告。
Ther Adv Neurol Disord. 2013 May;6(3):199-203. doi: 10.1177/1756285613475835.
2
Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up.鞘内注射巴氯芬治疗多发性硬化相关痉挛：长期随访。
J Rehabil Med. 2011 May;43(6):511-4. doi: 10.2340/16501977-0811.
3
Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis.难治性三叉神经痛对一名多发性硬化症患者的纳布西莫尔有反应。
Mult Scler Relat Disord. 2016 Jul;8:64-5. doi: 10.1016/j.msard.2016.05.004. Epub 2016 May 2.
4
Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin.鞘内注射巴氯芬对脊髓源性严重痉挛患者损伤、残疾及生活质量的长期影响（超过五年）
J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1553-7. doi: 10.1136/jnnp.2003.014282.
5
Effectiveness, Safety and Patients' Satisfaction of Nabiximols (Sativex) on Multiple Sclerosis Spasticity and Related Symptoms in a Swiss Multicenter Study.在瑞士多中心研究中，纳布西莫尔（Sativex）对多发性硬化痉挛及相关症状的有效性、安全性和患者满意度
J Clin Med. 2024 May 14;13(10):2907. doi: 10.3390/jcm13102907.
6
Long-term effects of intrathecal baclofen in multiple sclerosis.鞘内注射巴氯芬对多发性硬化症的长期影响。
Clin Neurol Neurosurg. 2016 Apr;143:121-5. doi: 10.1016/j.clineuro.2016.02.016. Epub 2016 Feb 16.
7
A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.一项关于巴氯芬和 THC:CBD 口腔喷雾剂对多发性硬化相关痉挛性步行障碍影响的综述。
Expert Rev Neurother. 2018 Oct;18(10):785-791. doi: 10.1080/14737175.2018.1510772. Epub 2018 Sep 20.
8
Early outcomes after intrathecal baclofen therapy in ambulatory patients with multiple sclerosis.鞘内注射巴氯芬治疗多发性硬化症门诊患者的早期结果。
J Neurosurg. 2018 Oct;129(4):1056-1062. doi: 10.3171/2017.5.JNS162925. Epub 2017 Dec 1.
9
Effect of nabiximols oromucosal spray (Sativex) on symptoms associated with multiple sclerosis-related spasticity: a case series.纳布西莫尔口腔喷雾剂（Sativex）对与多发性硬化相关痉挛有关症状的影响：病例系列研究
Drugs Context. 2024 Feb 14;13. doi: 10.7573/dic.2023-10-1. eCollection 2024.
10
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.纳比昔醇治疗运动神经元病患者痉挛症状的安全性和有效性（CANALS）：一项多中心、双盲、随机、安慰剂对照、2 期临床试验。
Lancet Neurol. 2019 Feb;18(2):155-164. doi: 10.1016/S1474-4422(18)30406-X. Epub 2018 Dec 13.
引用本文的文献
1
Biomedical Variables and Adaptation to Disease and Health-Related Quality of Life in Polish Patients with MS.波兰多发性硬化症患者的生物医学变量与疾病和健康相关生活质量的适应性。
Int J Environ Res Public Health. 2018 Nov 28;15(12):2678. doi: 10.3390/ijerph15122678.
2
Modulation of TLR3/TLR4 inflammatory signaling by the GABAB receptor agonist baclofen in glia and immune cells: relevance to therapeutic effects in multiple sclerosis.γ-氨基丁酸B受体激动剂巴氯芬对神经胶质细胞和免疫细胞中TLR3/TLR4炎症信号的调节作用：与多发性硬化症治疗效果的相关性
Front Cell Neurosci. 2015 Jul 28;9:284. doi: 10.3389/fncel.2015.00284. eCollection 2015.
本文引用的文献
1
Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.多发性硬化症的对症治疗：大麻素在治疗痉挛中的作用。
Ther Adv Neurol Disord. 2012 Sep;5(5):255-66. doi: 10.1177/1756285612453972.
2
Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease.解析大麻素受体 2 (CB2) 在健康和疾病中的免疫调节复杂性。
Immunol Res. 2011 Oct;51(1):26-38. doi: 10.1007/s12026-011-8210-5.
3
Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.δ-9-四氢大麻酚和大麻二酚口腔黏膜喷雾（Sativex）的滥用潜力和精神活性作用，一种新的大麻素药物。
Expert Opin Drug Saf. 2011 Sep;10(5):675-85. doi: 10.1517/14740338.2011.575778. Epub 2011 May 4.
4
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.一项纳比西莫司（Sativex®）作为附加治疗药物，用于治疗多发性硬化症引起的难治性痉挛的随机、双盲、安慰剂对照、平行组、富集设计研究。
Eur J Neurol. 2011 Sep;18(9):1122-31. doi: 10.1111/j.1468-1331.2010.03328.x. Epub 2011 Mar 1.
5
Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy.鞘内重复曲安奈德治疗以脊髓为主的多发性硬化症的获益：上脊髓萎缩预测。
Ther Adv Neurol Disord. 2009 Nov;2(6):42-9. doi: 10.1177/1756285609343480.
6
Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions.多发性硬化症症状的药物治疗：当前方法和未来方向。
Lancet Neurol. 2010 Dec;9(12):1182-1199. doi: 10.1016/S1474-4422(10)70249-0.
7
Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.多靶点药物 Sativex（纳比昔单抗）治疗多发性硬化痉挛的疗效和安全性的荟萃分析
Mult Scler. 2010 Jun;16(6):707-14. doi: 10.1177/1352458510367462.
8
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.一项针对患有多发性硬化症所致痉挛症状患者的Sativex双盲、随机、安慰剂对照、平行组研究。
Neurol Res. 2010 Jun;32(5):451-9. doi: 10.1179/016164109X12590518685660. Epub 2010 Mar 19.
9
Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.治疗性大麻素对多发性硬化症的精神病理学和认知影响：一项双盲、安慰剂对照、交叉研究。
Clin Neuropharmacol. 2009 Jan-Feb;32(1):41-7. doi: 10.1097/WNF.0B013E3181633497.
10
Multiple sclerosis, cannabinoids, and cognition.多发性硬化症、大麻素与认知
J Neuropsychiatry Clin Neurosci. 2008 Winter;20(1):36-51. doi: 10.1176/jnp.2008.20.1.36.
Zotero 插件